Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Description

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month.

Conditions

B-cell Acute Lymphoblastic Leukemia, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month.

A Phase 2 Randomized Trial of Caloric Restriction and Activity to Reduce Chemoresistance in B-cell Acute Lymphoblastic Leukemia

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Condition
B-cell Acute Lymphoblastic Leukemia
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Children's Hospital Los Angeles, Los Angeles, California, United States, 90027

Orange

Children's Hospital Orange County, Orange, California, United States, 92868

San Francisco

UCSF School of Medicine, San Francisco, California, United States, 94158

Denver

Colorado Children's Hospital, Denver, Colorado, United States, 80045

Atlanta

Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States, 30322

Chicago

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States, 60611

Baltimore

Johns Hopkins / Sydney Kimmel Cancer Center, Baltimore, Maryland, United States, 21231

Ann Arbor

C.S. Mott University of Michigan, Ann Arbor, Michigan, United States, 48109

Minneapolis

Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States, 55404

New York

Columbia University Medical Center, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must be ≥ 10.0 and \<26.0 years of age.
  • * Patients must have a diagnosis of de novo B-ALL
  • * Patients must have a M3 marrow (\>25% blasts by morphology) or at least 1,000/µL circulating leukemia cells in PB confirmed by Flow Cytometry (or other convincing evidence of a B-ALL diagnosis not meeting above criteria following central review by the Study Hematopathologist and Study Chair or Vice-Chair).
  • * The treatment regimen must be the first treatment attempt for B-ALL-
  • * Must be a multi-agent induction regimen inclusive of vincristine, glucocorticoid, pegaspargase/calaspargase, and daunorubicin or doxorubicin and with a planned duration \<35 days.
  • * Organ function must meet that required for initiation of chemotherapy
  • * Patients at diagnosis must meet Karnofsky \> 50% for patients \> 16 years of age and Lansky \> 50% for patients ≤ 16 years of age (or be expected to recover prior to Day 8) .
  • * If the patient is a female of childbearing potential, a negative urine or serum pregnancy test is required within two weeks prior to enrollment.
  • * Patient will be excluded if they are underweight at time of enrollment (BMI% \<5th percentile for age for patients age 10-19 years, BMI \<18.5 in patients 20-29 years).
  • * Patients with Down syndrome or a DNA fragility syndrome (such as Fanconi anemia, Bloom syndrome) will be excluded.
  • * Patient receiving a SJCRH-style "Total Therapy" regimen will be excluded.
  • * Patients receiving anti-CD20 monoclonal antibody therapy during induction therapy.
  • * Patients will be excluded if they received treatment for a previous malignancy.
  • * Patient will be excluded if they are pregnant.
  • * Patient will be excluded if they have a pre-diagnosis requirement for enteral or parenteral supplementation .
  • * Patient will be excluded due to inability to perform the intervention (e.g., specific nutritional needs, severe developmental delay, paraplegia)
  • * Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results

Ages Eligible for Study

10 Years to 25 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Etan Orgel,

Study Record Dates

2031-10-15